The Experts below are selected from a list of 246 Experts worldwide ranked by ideXlab platform
David Comas - One of the best experts on this subject based on the ideXlab platform.
-
worldwide genetic variation in dopamine and Serotonin Pathway genes implications for association studies
American Journal of Medical Genetics, 2008Co-Authors: Michelle Gardner, Jaume Bertranpetit, David ComasAbstract:The dopamine and Serotonin systems are two of the most important neurotransmitter Pathways in the human nervous system and their roles in controlling behavior and mental status are well accepted. Genes from both systems have been widely implicated in psychiatric and behavioral disorders, with numerous reports of associations and almost equally as numerous reports of the failure to replicate a previous finding of association. We investigate a set of 21 dopamine and Serotonin genes commonly tested for association with psychiatric disease in a set of 39 worldwide populations representing global genetic diversity to see whether the failure to replicate findings of association may be explained by population based differences in allele frequencies and linkage disequilibrium (LD) in this gene set. We present results demonstrating a surprising homogeneity of the allele frequencies across worldwide populations in these genes. LD both for populations within continent groupings and across continental regions also showed a remarkable similarity. These findings taken together suggest that ethnic differences in these parameters are not major generators of artifacts in genetic association studies of psychiatric disorders with genes from this set. Therefore, factors other than ethnic differences in genetic variation may explain the discrepancies reported among genetic association studies with this set of genes to date. The transferability of tagSNPs defined in the HapMap populations to other worldwide populations was also investigated and found to be high. A list of tagSNPs per gene and continental region is proposed providing a guide for future association studies with these genes. 2008 Wiley-Liss, Inc.
-
Worldwide genetic variation in dopamine and Serotonin Pathway genes: implications for association studies.
American journal of medical genetics. Part B Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2008Co-Authors: Michelle Gardner, Jaume Bertranpetit, David ComasAbstract:The dopamine and Serotonin systems are two of the most important neurotransmitter Pathways in the human nervous system and their roles in controlling behavior and mental status are well accepted. Genes from both systems have been widely implicated in psychiatric and behavioral disorders, with numerous reports of associations and almost equally as numerous reports of the failure to replicate a previous finding of association. We investigate a set of 21 dopamine and Serotonin genes commonly tested for association with psychiatric disease in a set of 39 worldwide populations representing global genetic diversity to see whether the failure to replicate findings of association may be explained by population based differences in allele frequencies and linkage disequilibrium (LD) in this gene set. We present results demonstrating a surprising homogeneity of the allele frequencies across worldwide populations in these genes. LD both for populations within continent groupings and across continental regions also showed a remarkable similarity. These findings taken together suggest that ethnic differences in these parameters are not major generators of artifacts in genetic association studies of psychiatric disorders with genes from this set. Therefore, factors other than ethnic differences in genetic variation may explain the discrepancies reported among genetic association studies with this set of genes to date. The transferability of tagSNPs defined in the HapMap populations to other worldwide populations was also investigated and found to be high. A list of tagSNPs per gene and continental region is proposed providing a guide for future association studies with these genes.
Vita Dolžan - One of the best experts on this subject based on the ideXlab platform.
-
genetic variability of Serotonin Pathway associated with schizophrenia onset progression and treatment
American Journal of Medical Genetics, 2020Co-Authors: Karin Hrovatin, Tanja Kunej, Vita DolžanAbstract:Schizophrenia (SZ) onset and treatment outcome have important genetic components, however individual genes do not have strong effects on SZ phenotype. Therefore, it is important to use the Pathway-based approach and study metabolic and signaling Pathways, such as dopaminergic and serotonergic. Serotonin Pathway has an important role in brain signaling, nevertheless, its role in SZ is not as thoroughly examined as that of dopamine Pathway. In this study, we reviewed Serotonin Pathway genes and genetic variations associated with SZ, including variations at DNA, RNA, and epigenetic level. We obtained 30 Serotonin Pathway genes from Kyoto encyclopedia of genes and genomes and used these genes for the literature review. We extracted 20 protein coding Serotonin Pathway genes with genetic variations associated with SZ onset, development, and treatment from 31 research papers. Genes associated with SZ are present on all levels of Serotonin Pathway: Serotonin synthesis, transport, receptor binding, intracellular signaling, and reuptake; however, regulatory genes are poorly researched. We summarized common challenges of genetic association studies and presented some solutions. The analysis of reported Serotonin Pathway-SZ associations revealed lack of information about certain Serotonin Pathway genes potentially associated with SZ. Furthermore, it is becoming clear that interactions among Serotonin Pathway genes and their regulators may bring further knowledge about their involvement in SZ.
-
alcohol dependence and genetic variability in the Serotonin Pathway among currently and formerly alcohol dependent males
Neuropsychobiology, 2015Co-Authors: Anja Plemenitas, Vita Dolžan, Matej Kastelic, Stefano Porcelli, Alessandro Serretti, Blanka Kores PlesnicarAbstract:Background: Genes involved in the Serotonin Pathway may determine the susceptibility to alcohol dependence and its severity. The present study explored whether sp
Alessandro Serretti - One of the best experts on this subject based on the ideXlab platform.
-
alcohol dependence and genetic variability in the Serotonin Pathway among currently and formerly alcohol dependent males
Neuropsychobiology, 2015Co-Authors: Anja Plemenitas, Vita Dolžan, Matej Kastelic, Stefano Porcelli, Alessandro Serretti, Blanka Kores PlesnicarAbstract:Background: Genes involved in the Serotonin Pathway may determine the susceptibility to alcohol dependence and its severity. The present study explored whether sp
-
No effect of Serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression.
Psychiatry Investigation, 2013Co-Authors: Alessandro Serretti, Stefano Porcelli, Chiara Fabbri, Silvia Pellegrini, Pierluigi Politi, Silvio Bellino, Marco Menchetti, Veronica Mariotti, Cristina Demi, Valentina MartinelliAbstract:Objective Gene variants within the Serotonin Pathway have been associated with major depressive disorder (MDD) treatment outcomes, however a possible different modulation on pharmacological or psychological treatments has never been investigated.
-
the influence of Serotonin transporter promoter polymorphism sertpr and other polymorphisms of the Serotonin Pathway on the efficacy of antidepressant treatments
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2005Co-Authors: Alessandro Serretti, Francesco Benedetti, Raffaella Zanardi, Enrico SmeraldiAbstract:The definition of a genetic liability profile for specific antidepressant treatment will soon be available offering considerable help in early detection of effective therapy in affective disorders. The search for genetic factors predisposing to drug response or side-effects in affective disorders started only in the last few years. The efficacy of antidepressant action was associated with several polymorphisms, located on coding genes of proteins thought to be involved in the different mechanisms of action of antidepressant treatments. Among these, gene variants in sequences of Serotonin Pathway proteins were candidate, both for the well known evidence of its involvement in the development of depressive symptomathology and for the wide-world use of selective Serotonin reuptake inhibitors as first choice treatment of depression. A polymorphism in the promoter region of the Serotonin transporter (SERTPR) was independently associated with efficacy for a range of treatments, other polymorphism located on the tryptophan hydroxylase gene, 5-HT2a receptor and G-protein beta 3 showed some association, while other candidate genes were not associated with treatment efficacy. Possible liability genes controlling at least to some extent both acute and long-term treatment were identified, and the further objective is to identify other candidate genes in order to define individualized treatments according to genetic profile in a future. The present paper reviews the pharmacogenetic studies published to date, focusing the attention on the serotonergic Pathway.
Marcus R Munafo - One of the best experts on this subject based on the ideXlab platform.
-
genetic variation in the Serotonin Pathway and smoking cessation with nicotine replacement therapy new data from the patch in practice trial and pooled analyses
Drug and Alcohol Dependence, 2008Co-Authors: Sean P David, Elaine C Johnstone, Michael F Murphy, Paul Aveyard, Caryn Lerman, Marcus R MunafoAbstract:The Serotonin Pathway has been implicated in nicotine dependence and may influence smoking cessation. Therefore, 792 cigarette smokers from the Patch in Practice trial were genotyped for the tryptophan hydroxylase (TPH1 A779C), Serotonin transporter (SLC6A4 5-HTTLPR), and 5-HT1A (HTR1A C-1019G) polymorphisms. Cox regression analysis did not demonstrate significant effects of any of the three genotypes on relapse to smoking: TPH1 (Reference AA; AC: hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.78, 1.24, p = 0.90; CC: HR 0.93, 95% CI 0.73, 1.18, p = 0.55); 5-HTTLPR (Reference LL; SL: HR 1.01, 95% CI 0.85, 1.20, p = 0.90; SS: HR 1.13, 95% CI 0.91, 1.39, p = 0.27); HTR1A (Reference CC; CG: HR 1.04, 95% CI 0.86, 1.25, p = 0.70; GG: HR 1.01, 95% CI 0.82, 1.24, p = 0.93). Moreover, pooled analyses of data from all three extant pharmacogenetic NRT trials (N = 1398) found no significant effect of 5-HTTLPR genotype on continuous abstinence at 12-week (Reference LL; SL: odds ratio (OR) = 1.25, 95% CI 0.89, 1.74, p = 0.19; SS: OR = 1.31, 95% CI 0.86, 1.98, p = 0.21) or 26-week follow-up (Reference LL; SL: OR = 0.93, 95% CI 0.64, 1.33, p = 0.68; SS: OR = 1.00, 95% CI 0.63, 1.58, p = 1.00). These data do not support a statistically or clinically significant moderating effect of these specific 5-HT Pathway genetic variants on smoking cessation. However, the possibility remains that other variants in these or other 5-HT genes may influence NRT efficacy for smoking cessation in treatment seeking smokers. © 2008 Elsevier Ireland Ltd. All rights reserved.
-
Genetic variation in the Serotonin Pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses.
Drug and alcohol dependence, 2008Co-Authors: Sean P David, Elaine C Johnstone, Michael F Murphy, Paul Aveyard, Caryn Lerman, Marcus R MunafoAbstract:The Serotonin Pathway has been implicated in nicotine dependence and may influence smoking cessation. Therefore, 792 cigarette smokers from the Patch in Practice trial were genotyped for the tryptophan hydroxylase (TPH1 A779C), Serotonin transporter (SLC6A45-HTTLPR), and 5-HT1A (HTR1A C-1019G) polymorphisms. Cox regression analysis did not demonstrate significant effects of any of the three genotypes on relapse to smoking: TPH1 (Reference AA; AC: hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.78, 1.24, p=0.90; CC: HR 0.93, 95% CI 0.73, 1.18, p=0.55); 5-HTTLPR (Reference LL; SL: HR 1.01, 95% CI 0.85, 1.20, p=0.90; SS: HR 1.13, 95% CI 0.91, 1.39, p=0.27); HTR1A (Reference CC; CG: HR 1.04, 95% CI 0.86, 1.25, p=0.70; GG: HR 1.01, 95% CI 0.82, 1.24, p=0.93). Moreover, pooled analyses of data from all three extant pharmacogenetic NRT trials (N=1398) found no significant effect of 5-HTTLPR genotype on continuous abstinence at 12-week (Reference LL; SL: odds ratio (OR)=1.25, 95% CI 0.89, 1.74, p=0.19; SS: OR=1.31, 95% CI 0.86, 1.98, p=0.21) or 26-week follow-up (Reference LL; SL: OR=0.93, 95% CI 0.64, 1.33, p=0.68; SS: OR=1.00, 95% CI 0.63, 1.58, p=1.00). These data do not support a statistically or clinically significant moderating effect of these specific 5-HT Pathway genetic variants on smoking cessation. However, the possibility remains that other variants in these or other 5-HT genes may influence NRT efficacy for smoking cessation in treatment seeking smokers.
Michelle Gardner - One of the best experts on this subject based on the ideXlab platform.
-
worldwide genetic variation in dopamine and Serotonin Pathway genes implications for association studies
American Journal of Medical Genetics, 2008Co-Authors: Michelle Gardner, Jaume Bertranpetit, David ComasAbstract:The dopamine and Serotonin systems are two of the most important neurotransmitter Pathways in the human nervous system and their roles in controlling behavior and mental status are well accepted. Genes from both systems have been widely implicated in psychiatric and behavioral disorders, with numerous reports of associations and almost equally as numerous reports of the failure to replicate a previous finding of association. We investigate a set of 21 dopamine and Serotonin genes commonly tested for association with psychiatric disease in a set of 39 worldwide populations representing global genetic diversity to see whether the failure to replicate findings of association may be explained by population based differences in allele frequencies and linkage disequilibrium (LD) in this gene set. We present results demonstrating a surprising homogeneity of the allele frequencies across worldwide populations in these genes. LD both for populations within continent groupings and across continental regions also showed a remarkable similarity. These findings taken together suggest that ethnic differences in these parameters are not major generators of artifacts in genetic association studies of psychiatric disorders with genes from this set. Therefore, factors other than ethnic differences in genetic variation may explain the discrepancies reported among genetic association studies with this set of genes to date. The transferability of tagSNPs defined in the HapMap populations to other worldwide populations was also investigated and found to be high. A list of tagSNPs per gene and continental region is proposed providing a guide for future association studies with these genes. 2008 Wiley-Liss, Inc.
-
Worldwide genetic variation in dopamine and Serotonin Pathway genes: implications for association studies.
American journal of medical genetics. Part B Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2008Co-Authors: Michelle Gardner, Jaume Bertranpetit, David ComasAbstract:The dopamine and Serotonin systems are two of the most important neurotransmitter Pathways in the human nervous system and their roles in controlling behavior and mental status are well accepted. Genes from both systems have been widely implicated in psychiatric and behavioral disorders, with numerous reports of associations and almost equally as numerous reports of the failure to replicate a previous finding of association. We investigate a set of 21 dopamine and Serotonin genes commonly tested for association with psychiatric disease in a set of 39 worldwide populations representing global genetic diversity to see whether the failure to replicate findings of association may be explained by population based differences in allele frequencies and linkage disequilibrium (LD) in this gene set. We present results demonstrating a surprising homogeneity of the allele frequencies across worldwide populations in these genes. LD both for populations within continent groupings and across continental regions also showed a remarkable similarity. These findings taken together suggest that ethnic differences in these parameters are not major generators of artifacts in genetic association studies of psychiatric disorders with genes from this set. Therefore, factors other than ethnic differences in genetic variation may explain the discrepancies reported among genetic association studies with this set of genes to date. The transferability of tagSNPs defined in the HapMap populations to other worldwide populations was also investigated and found to be high. A list of tagSNPs per gene and continental region is proposed providing a guide for future association studies with these genes.
